中生方政NBF品牌怎么样 申请店铺

更新时间:2024-10-28
中生方政NBF是哪个国家的品牌?「中生方政NBF」是 中生方政生物技术股份有限公司 旗下著名品牌。该品牌发源于江苏省泰州市,由创始人郭光华在2009-09-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
中生方政NBF怎么样

中生方政生物技术股份有限公司,成立于2009年,是一家集诊断试剂、生物医药、预防性疫苗及仪器设备的研发和生产为一体的生物医药技术企业。占地面积近55000平方米,建筑面积25700 平方米。研发总部设立在美国,主要从事具有国际前沿技术水平的体外诊断试剂的开发和研制。已建成核酸分子诊断试剂生产车间、金标车间、酶联免疫诊断试剂生产车间、中试(设备)车间、动力中心、动物实验楼、综合楼(研发中心)等标准化GMP生产车间及现代化办公配套设施,现已完成规模化产业基地的建设,形成了年产分子诊断试剂1000万人份和分子检测设备1000台的生产能力。

中生方政长期专注于临床分子诊断技术的开发。在国内IVD行业,中生方政是为数不多拥6项以上注册文号的生产企业,实现了产品价格多层次化,产品结构梯队化,可以满足不同客户的检测需求和价格承受能力,具有较宽的市场辐射面,为市场纵深开发打下了良好基础。

作为前沿技术创新主导型高科技企业,公司依托自主研发及联合开发等多种方式,创建了成熟稳定的新型核酸检测技术平台,并已先期开发出人乳头瘤病毒(HPV)临床检测试剂,成为国内首个利用恒温技术检测HPV病毒的产品。目前公司已获得国家食品药品监督总局颁发的15种型别人乳头瘤病毒和16/18型人乳头瘤病毒核酸检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)基因分型检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)核酸检测试剂盒(恒温扩增-荧光法)等产品注册证书。同时,公司还开发出配套的恒温荧光检测设备。依托于该技术平台,公司正在努力拓展产品线,逐步推进试剂和仪器的“系列化”、“一体化”发展目标。

中生方政将本着“用心、专注、创新、服务”的企业理念和“成为国内在体外诊断试剂产业领域最具创新研发能力的优秀产品与服务供应商”的发展愿景,“资本加创新”双轮驱动的发展战略,以及“质量第一 追求卓越”的管理理念,愿同社会各界合作共赢,回馈股东、客户和员工,进而为推动我国医学检验产业及健康医疗事业的发展做出新的贡献。


Zhongsheng Fangzheng Biotechnology Co., Ltd., founded in 2009, is a biomedical technology enterprise integrating research and development and production of diagnostic reagents, biomedicine, preventive vaccines and equipment. It covers an area of nearly 55000 square meters and a building area of 25700 square meters. R & D headquarters is established in the United States, mainly engaged in the development and development of in vitro diagnostic reagents with international cutting-edge technology level. Standardized GMP production workshops and modern office facilities have been built, such as nucleic acid molecular diagnostic reagent production workshop, gold standard workshop, enzyme-linked immunodiagnostic reagent production workshop, pilot test (equipment) workshop, power center, animal laboratory building, comprehensive building (R & D center). The construction of large-scale industrial base has been completed, with an annual output of 10 million people and molecules of molecular diagnostic reagents Production capacity of 1000 testing equipment. Zhongsheng Fangzheng has long focused on the development of clinical molecular diagnosis technology. In the domestic IVD industry, Zhongsheng Fangzheng is one of the few manufacturers with more than 6 registered numbers. It has realized multi-level product price and echelon product structure, which can meet the testing needs and price tolerance of different customers. It has a wide market radiation and lays a good foundation for in-depth market development. As a leading high-tech enterprise of cutting-edge technology innovation, the company has established a mature and stable new nucleic acid detection technology platform relying on independent research and development and joint development, and has developed the clinical detection reagent of human papillomavirus (HPV) in advance, becoming the first domestic product using constant temperature technology to detect HPV virus. At present, the company has obtained product registration certificates issued by the State Food and drug administration, such as 15 types of HPV and 16 / 18 HPV nucleic acid detection kits (constant temperature amplification fluorescence method), HPV gene typing detection kits (constant temperature amplification fluorescence method), HPV nucleic acid detection kits (constant temperature amplification fluorescence method), etc Book. At the same time, the company also developed a complete set of constant temperature fluorescence detection equipment. Relying on this technology platform, the company is striving to expand its product line and gradually promote the development goals of "serialization" and "integration" of reagents and instruments. Zhongsheng Fangzheng is willing to cooperate with all walks of life for win-win cooperation and feedback with the corporate philosophy of "heart, focus, innovation and service", the development vision of "becoming the best product and service provider with the most innovative R & D ability in the field of in vitro diagnostic reagent industry in China", the development strategy of "capital plus innovation" driven by two wheels, and the management concept of "quality first pursuit of excellence" Shareholders, customers and employees will make new contributions to the development of China's medical testing industry and health care industry.

本文链接: https://brand.waitui.com/2c7dece2d.html 联系电话:052380766900

千城特选小程序码

7×24h 快讯

“灵生科技”获千万级天使轮融资

36氪获悉,专注具身智能的“灵生科技”近日宣布完成千万级天使轮融资,投资方包括天容海色、万物为创投、夸克电力。融资资金将用于灵生类脑产品线研发。

28分钟前

康斯特:预计明年设备更新政策会逐步产生落地效果

康斯特在业绩说明会上表示,针对美国大选落地后加税程度存在一定不确定性,新加坡公司已全力加强建设,计划在明年1月中旬前,非美国市场的订单全部由新加坡子公司管理;国内市场方面,三季度的订单会对四季度的业绩形成一定助力,但低价竞争仍是主要问题,今年二季度陆续出台的产业政策目前体感有限,设备更新政策对仪表行业的规模增长有一定的迟滞期,预计明年会逐步产生落地效果。(证券时报)

28分钟前

沪深两市成交额突破1.5万亿元

36氪获悉,截至发稿,沪深两市成交额突破1.5万亿元,较上一交易日此时放量超600亿元。

28分钟前

阿里影业接盘华谊兄弟所持东阳美拉70%股份

36氪获悉,企查查App显示,近日,浙江东阳美拉传媒有限公司发生工商变更,华谊兄弟退出股东,退出前持股70%,新增北京阿里巴巴影业文化有限公司为股东,同时公司法定代表人由王忠磊变更为李捷。企查查信息显示,该公司成立于2015年,注册资本500万元人民币,经营范围包含:影视文化信息咨询;影视剧本创作、策划、交易等。

28分钟前

多家钢企酝酿并购重组,中钢协将出台鼓励政策

“很多企业在考虑强强联手,并购重组。”中国钢铁工业协会(以下简称“中钢协”)副秘书长兼产业运行部主任陈玉千透露,“行业内有不少优势企业有能力且有意愿通过主动探索重组,来争取新的发展机遇。”他同时透露,中钢协正在组织行业力量,根据企业提出的意见深入研究,并提出有针对性和可操作性的支持政策。(中国经营报)

28分钟前

本页详细列出关于中生方政NBF的品牌信息,含品牌所属公司介绍,中生方政NBF所处行业的品牌地位及优势。
咨询